S4V2 will be tested for safety and preliminary efficacy in approximately 120 healthy Shigella -naïve participants aged 18 to 50 years at three sites in the United States. The study, sponsored and ...

Saint-Herblain (France), November 12, 2024 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

The vaccine contains a strain of chikungunya virus that has been attenuated. IXCHIQ comes from Valneva Canada and it is ...

Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage ...

Valneva (VALN) has released an update. Valneva is set to showcase its pioneering chikungunya vaccine, IXCHIQ®, at several esteemed scientific forums this quarter, highlighting two-year antibody ...

With a promising pipeline, including the S4V2 Shigella vaccine candidate, Valneva is poised for growth and strategic expansion. TipRanks is the most comprehensive data set of sell side analysts ...

Valneva SE (INRLF) reports a significant turnaround with increased sales and a positive operating profit, despite challenges ...

Valneva’s sales in the first nine months of 2024 were €112.5 million compared to €106.1 million (€100.4 million excluding final COVID-19 vaccine sales) in the first nine months of 2023.

Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech ...